

Advanced Innovative Partners Continues the Fight Against Breast Cancer

Advanced Innovative Partners Continues the Fight Against Breast Cancer

BOYNTON BEACH, FLORIDA, UNITED STATES, October 27, 2021 /EINPresswire.com/ -- October is National Breast Cancer Month. Miami-based Advanced Innovative Partners continues its fight against breast cancer and is advancing development of a novel treatment for Human Epidermal Growth Factor 2 (HER2) Breast Cancer. There are nearly 200,000 women living with metastatic HER2+ breast cancer in the U.S. alone, and millions more around the world. AIP's HER2-tumor targeted radiotherapy could reduce breast cancer morbidity and mortality in those suffering from this disease. While advances in imaging and therapy have improved the survival of patients with breast cancer, the five-year survival for patients with metastatic breast cancer still hovers around 20%.



Breast cancers which express the HER2 receptor are particularly aggressive and remain difficult to treat. Over the past decade, HER2-targeted therapies have demonstrated the ability to prolong patient survival, yet almost all therapies will eventually fail patients leading to progression and possible death. There is a great need for novel, safe and effective therapies, said Roseanne Satz, AIP's Chief Executive Officer. We are very pleased to be contributing to the fight against breast cancer. Promising results in our studies to diagnose and treat HER2-positive breast cancer using targeted radioligand therapy has the potential to successfully treat patients with metastatic cancer. This medication binds to the HER2 molecule on the surface of cancer cells and delivers enough radiation to kill breast cancer cells without collateral effects".

AIP's Phase I and Phase II Diagnostic and Theranostic studies aim to determine the anti-tumor activity of targeted therapy using Lutetium-177- $\alpha\text{V}\beta\text{3}$ -IAP, as second-or third-line treatment and to evaluate progression free survival. The short-term goals are to provide clinical safety and efficacy data required by the FDA for the initiation of Phase III clinical trials and the submission of

an NDA for AIP's HER2-targeted radionuclide therapy.

About AIP: Advanced Innovative Partners is a late-stage clinical biotechnology company focused on development diagnostics and companion therapeutics in oncology, neurology, rare pediatric diseases, and medical countermeasures. True to our name, our mission is to deliver transformative science to people with underserved medical needs, making a difference in their lives. The Company's robust nuclear medicine product portfolio includes specialty pharmaceuticals enabling personalized medicine. For additional information about AIP please visit www.advancedinnovativepartners.com

Note Regarding Forward-Looking Statements: This press release contains "forward-looking" statements that involve substantial risks and uncertainties. All statements other than statements of historical facts, including statements regarding our future financial condition, timing for and outcomes of clinical results, business strategy and plans and objectives for future operations, are forward-looking statements. These forward-looking statements include terminology such as "believe," "will," "may," "estimate," "continue," "anticipate," "contemplate," "intend," "target," "project," "should," "plan," "expect," "predict," "could," "potentially" or the negative of these terms. Forward-looking statements are our current statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other anticipating significant milestones in 2020 and 2021, the timing of our ongoing and planned clinical development, including our ability to support the launch of a new product and ship to specialty pharmacies.

Contact: Sylvia.Mergui@advancedinnovativepartners.com

Telephone: (305)807-8266

Dr. Sylvia Mergui

Advanced Innovative Partners

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/554894884>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 IPD Group, Inc. All Right Reserved.